However , patients in the dacomitinib group had longer progression-free survival than those in the placebo group ( median @ months -LSB- @-@ -RSB- vs @ months -LSB- @-@ -RSB- , respectively ; HR @ -LSB- @ % CI @-@ -RSB- ; p < @ ) , and a significantly greater proportion of patients in the dacomitinb group achieved an objective response than in the placebo group ( @ -LSB- @ % -RSB- of @ patients vs three -LSB- @ % -RSB- of @ patients , respectively ; p = @ ) .